A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice

Simple item page
dc.contributor.authorCoria, Lorena M.en
dc.contributor.authorSaposnik, Lucas M.en
dc.contributor.authorPueblas Castro, Celesteen
dc.contributor.authorCastro, Eliana F.en
dc.contributor.authorBruno, Laura A.en
dc.contributor.authorStone, William B.en
dc.contributor.authorPerez, Paula S.en
dc.contributor.authorDarriba, Maria Lauraen
dc.contributor.authorChemes, Lucia B.en
dc.contributor.authorAlcain, Julietaen
dc.contributor.authorMazzitelli, Ignacioen
dc.contributor.authorVarese, Augustoen
dc.contributor.authorSalvatori, Melinaen
dc.contributor.authorAuguste, Albert J.en
dc.contributor.authoralvarez, Diego E.en
dc.contributor.authorPasquevich, Karina A.en
dc.contributor.authorCassataro, Julianaen
dc.date.accessioned2022-07-21T15:02:16Zen
dc.date.available2022-07-21T15:02:16Zen
dc.date.issued2022-02-28en
dc.description.abstractIn this work, we evaluated recombinant receptor binding domain (RBD)-based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus alum, AddaS03, AddaVax, or the combination of alum and U-Omp19: a novel Brucella spp. protease inhibitor vaccine adjuvant. Results show that the vaccine formulation composed of U-Omp19 and alum as adjuvants has a better performance: it significantly increased mucosal and systemic neutralizing antibodies in comparison to antigen plus alum, AddaVax, or AddaS03. Antibodies induced with the formulation containing U-Omp19 and alum not only increased their neutralization capacity against the ancestral virus but also cross-neutralized alpha, lambda, and gamma variants with similar potency. Furthermore, the addition of U-Omp19 to alum vaccine formulation increased the frequency of RBD-specific geminal center B cells and plasmablasts. Additionally, U-Omp19+alum formulation induced RBD-specific Th1 and CD8(+) T-cell responses in spleens and lungs. Finally, this vaccine formulation conferred protection against an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge of K18-hACE2 mice.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.3389/fimmu.2022.844837en
dc.identifier.issn1664-3224en
dc.identifier.other844837en
dc.identifier.pmid35296091en
dc.identifier.urihttp://hdl.handle.net/10919/111310en
dc.identifier.volume13en
dc.language.isoenen
dc.publisherFrontiersen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectadjuvanten
dc.subjectprotease inhibitoren
dc.subjectSARS- CoV-2en
dc.subjectU-Omp19en
dc.subjectgerminal center cellsen
dc.titleA Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Miceen
dc.title.serialFrontiers in Immunologyen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fimmu-13-844837.pdf
Size:
6.62 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Scholarly Works, Entomology
Scholarly Works, Center for Emerging, Zoonotic, and Arthropod-borne Pathogens (CeZAP)